JP2024518455A - アルツハイマー病の治療方法 - Google Patents

アルツハイマー病の治療方法 Download PDF

Info

Publication number
JP2024518455A
JP2024518455A JP2023568654A JP2023568654A JP2024518455A JP 2024518455 A JP2024518455 A JP 2024518455A JP 2023568654 A JP2023568654 A JP 2023568654A JP 2023568654 A JP2023568654 A JP 2023568654A JP 2024518455 A JP2024518455 A JP 2024518455A
Authority
JP
Japan
Prior art keywords
subject
administered
hydrochloride
donepezil hydrochloride
daily dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024518455A5 (https=
Inventor
エル． ロジャース，シャロン
Original Assignee
アミリエーディー ファーマ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アミリエーディー ファーマ，インコーポレイテッド filed Critical アミリエーディー ファーマ，インコーポレイテッド
Publication of JP2024518455A publication Critical patent/JP2024518455A/ja
Publication of JP2024518455A5 publication Critical patent/JP2024518455A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023568654A 2021-05-19 2022-05-19 アルツハイマー病の治療方法 Pending JP2024518455A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163190299P 2021-05-19 2021-05-19
US63/190,299 2021-05-19
US202163192398P 2021-05-24 2021-05-24
US63/192,398 2021-05-24
US202263331011P 2022-04-14 2022-04-14
US63/331,011 2022-04-14
PCT/US2022/030020 WO2022246059A1 (en) 2021-05-19 2022-05-19 Method of treating alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2024518455A true JP2024518455A (ja) 2024-05-01
JP2024518455A5 JP2024518455A5 (https=) 2025-05-27

Family

ID=84104208

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568654A Pending JP2024518455A (ja) 2021-05-19 2022-05-19 アルツハイマー病の治療方法

Country Status (8)

Country Link
US (3) US20220370443A1 (https=)
EP (1) EP4340834A4 (https=)
JP (1) JP2024518455A (https=)
KR (1) KR20240021760A (https=)
AU (1) AU2022275939A1 (https=)
CA (1) CA3217579A1 (https=)
MX (1) MX2023013537A (https=)
WO (1) WO2022246059A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512173A (ja) * 2008-12-15 2012-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アミロイド前駆体タンパク質の切断を誘導して新規断片を形成させる方法
JP2012526818A (ja) * 2009-05-11 2012-11-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ユビキチン化タンパク質レベルの減少方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60006145T2 (de) * 1999-07-30 2004-06-09 Zenyaku Kogyo K.K. Azaindolizinon-derivate und agenzien zur verbesserung der kognitiver fähigkeiten,die dieselben als aktive inhaltstoffe enthalten
WO2012094612A1 (en) * 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Method of treating essential tremor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512173A (ja) * 2008-12-15 2012-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アミロイド前駆体タンパク質の切断を誘導して新規断片を形成させる方法
JP2012526818A (ja) * 2009-05-11 2012-11-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ユビキチン化タンパク質レベルの減少方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CUMMINGS, J. L. ET AL.: "High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug P", CNS NEUROSCIENCE & THERAPEUTICS, vol. 19, no. 5, JPN6026013269, 2013, pages 294 - 301, ISSN: 0005831987 *
GAUTHIER, S. ET AL.: "Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer’s Disease: A Randomize", JOURNAL OF ALZHEIMER'S DISEASE, JPN6026013266, 2015, pages 473 - 481, ISSN: 0005831985 *
JAYARAJAN, P. ET AL.: "P1-089: SUVN-502 + DONEPEZIL + MEMANTINE (TRIPLE COMBINATION): FIRST-IN-CLASS AND A PROMISING NEW AP", AAIC SUNDAY POSTER ABSTRACT, JPN6026013267, 2019, pages 1 - 089, ISSN: 0005831986 *
YAMAGUCHI, Y. ET AL.: "Combination Effects of ZSET1446/ST101 With Memantine on Cognitive Function and Extracellular Acetylc", JOURNAL OF PHARMACOLOGICAL SCIENCES, vol. 123, no. 4, JPN6026013265, 2013, pages 347 - 355, ISSN: 0005831984 *

Also Published As

Publication number Publication date
AU2022275939A1 (en) 2023-11-16
CA3217579A1 (en) 2022-11-24
WO2022246059A1 (en) 2022-11-24
EP4340834A1 (en) 2024-03-27
US20220370443A1 (en) 2022-11-24
US20250375444A1 (en) 2025-12-11
EP4340834A4 (en) 2025-04-02
MX2023013537A (es) 2024-02-06
KR20240021760A (ko) 2024-02-19
US20240156812A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
CN107669668A (zh) 治疗多发性硬化症的组合疗法
US20180117148A1 (en) Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
US20110319384A1 (en) Pharmaceutical Compositions
JP7436524B2 (ja) ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物
RS51540B (sr) Memantin za lečenje blage do umerene alzhajmerove bolesti
CN114072945A (zh) 用于治疗精神障碍、行为障碍、认知障碍的新型药物组合物和方法
JP2020510675A (ja) ミトコンドリア起源のｒｏｓの産生の特異的阻害剤を使用した、薬物誘発ｑｔ間隔延長に関連するリスクの予防
EP4091607A1 (en) Methods for treating central nervous system disorders with muscarinic receptor activator xanomeline and antipsychotics
US20220370454A1 (en) Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics
US20100298397A1 (en) Method of treatment of obsessive compulsive disorder with ondansetron
JP2024518455A (ja) アルツハイマー病の治療方法
HK40103192A (zh) 治疗阿尔茨海默病的方法
CN119730840A (zh) 用于治疗重度抑郁症的1-(萘-2-基)-3-氮杂双环[3.1.0]己烷
CN117529318A (zh) 治疗阿尔茨海默病的方法
JP2007537294A (ja) Ｇａｂａｂレセプターアンタゴニストとアセチルコリンエステラーゼインヒビターとの同時投与により認識機能を改善するための方法
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合
CA3162952C (en) Treating behavioral and psychological symptoms in dementia patients
RU2845317C1 (ru) Способ лечения постковидного синдрома
Capsules Pr APO-FINGOLIMOD
JP2019094304A (ja) オートファジー誘導剤
Casaer et al. Risperidone in the treatment of childhood autistic disorder: an open pilot study
WO2024081828A1 (en) Methods of reducing physical dependence to neuropsychiatric treatments
Patel Dhaval et al. PHARMA SCIENCE MONITOR
HK40071665A (en) Treating behavioral and psychological symptoms in dementia patients
WO2019023318A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS USING PYRIDOSTIGMINE AND AN ANTAGONIST OF NK-1 FOR TREATING SEVERE MYASTHENIA

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260402